期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 10, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s13045-016-0379-6
关键词
Adoptive cell therapy; Adverse effects; Switchable dual-receptor T cell; Bifunctional molecule; Immune checkpoint blockade
资金
- Project Program of State Key Laboratory of Natural Medicines in China [SKLNMBZ201403]
- National Science and Technology Major Projects of New Drugs in China [2012ZX09103301-004, 2014ZX09508007]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged as a very promising approach to combating cancer. Despite its ability to eliminate tumors shown in some clinical trials, CAR-T cell therapy involves some significant safety challenges, such as cytokine release syndrome (CRS) and on-target, off-tumor toxicity, which is related to poor control of the dose, location, and timing of T cell activity. In the past few years, some strategies to avoid the side effects of CAR-T cell therapy have been reported, including suicide gene, inhibitory CAR, dual-antigen receptor, and the use of exogenous molecules as switches to control the CAR-T cell functions. Because of the advances of the CAR paradigm and other forms of cancer immunotherapy, the most effective means of defeating the cancer has become the integration therapy with the combinatorial control system of switchable dual-receptor CAR-T cell and immune checkpoint blockade.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据